由于过继转移的自然杀伤(NK)细胞寿命较短,副作用较少,并且对AML具有内在的CAR非依赖性杀伤能力,因此CD33-CAR-NK细胞就成了一种有前景的替代品。 2022年4月,Blood cancer journal期刊上发表了题为“Primary CD33-targeting CAR-NK cells ...
急性髓系白血病(Acute myeloid leukemia,AML)是最常见的白血病类型之一,常见于老年人,男性发病率高于女性。AML的特征在于快速增长的异常细胞,积聚在骨髓和血液中,从而干扰正常细胞,常见的临床症状包括感到疲倦、呼吸急促、容易瘀伤和出血以及感染风险增加。AML目前的主要治疗...
三个强劲靶点直击AML— CD33,CD123,CLEC12A (Acute Myeloid Leukemia,AML)是一种髓系造血干/祖细胞恶性疾病,长期以来,一直采用蒽环类和阿糖胞苷化疗治疗轻度患者,使用造血干细胞转移来治疗中、高危患者,其中,老年患者(≥60岁)和临床表现不佳的患者死亡率较高,5年总生存率约为10%。由于急性髓细胞白血病的异质性,导...
人Human CD33 分子靶点信息 分子名:CD33, CD33 molecule 别称: CD33 antigen (gp67) CD33 molecule transcript FLJ00391 gp67 myeloid cell surface antigen CD33 p67 sialic acid binding Ig-like lectin 3 sialic acid-binding Ig-like lectin 3 SIGLEC-3 ...
急性髓系白血病(Acute myeloid leukemia,AML)是最常见的白血病类型之一,常见于老年人,男性发病率高于女性。AML的特征在于快速增长的异常细胞,积聚在骨髓和血液中,从而干扰正常细胞,常见的临床症状包括感到疲倦、呼吸急促、容易瘀伤和出血以及感染风险增加。AML目前的主要治疗手段包括化疗和造血干细胞移植,如常用的“DA3+7...
1.Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORT...
参考文献 Smith MJ, et al. "The role of CD33 in modulating immune responses in cancer and infection." ImmunoTargets and Therapy, 2020.Paul SP, et al. "CD33 in health and disease." Biochemical Society Transactions, 2021.Taylor VC, et al. "CD33 as a therapeutic target in acute myeloid ...
[7] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016.127(20): 2391-2405. 【主创团队】 作者:小辛巴 编辑:Wendy 排版:Jacquel...
[7] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016.127(20): 2391-2405. 识别微信二维码,添加抗体圈小编,符合条件者即可加入抗...
1.Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9): 972-979....